As the President of Vivreon Biosciences, Dr. Greenberg's research interest is lead optimization and pre-clinical development of small molecule inhibitors of the Ca2+ release-activated Ca2+ (CRAC) channel. The CRAC channel is a molecular target required for chronic microgliosis, and Vivreon Biosciences is the first company to pursue this target for the treatment of Parkinson’s disease. Dr. Greenberg has led the Vivreon team in assay development, identification of a series of compounds that block CRAC channel function with nanomolar potency, and submission of patents. He is the principal investigator on all Vivreon grants, including awards from Johnson and Johnson Innovation, National Institute on Aging, National Cancer Institute, National Institute of Allergy and Infectious Disease, Alzheimer’s Drug Discovery Foundation and The Michael J. Fox Foundation.
Dr. Greenberg earned his PhD and completed his postdoctoral training in physiology and biophysics at University of California, Irvine.